PHI with Axillary metastases
How does this condition affect your private health insurance?
Achselmetastasen, or axillary metastases, refer to the spread of cancer cells from a primary tumor to the lymph nodes located in the armpit. This is a critical indicator of cancer progression, often signifying regional advancement and impacting staging and prognosis. The most common primary sources include breast cancer and melanoma, though other cancers like lung or gastrointestinal can also metastasize here. Diagnosis typically involves physical examination, imaging (ultrasound, MRI, PET scan), and biopsy. Their presence necessitates aggressive treatment strategies, often involving surgery (axillary lymph node dissection), radiation therapy, and systemic therapies like chemotherapy, hormone therapy, or targeted therapy to control the disease and prevent further dissemination. Management aims to improve survival and quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Days to weeks for diagnosis and initial treatment planning.
Duration of Illness (Lifetime)
Chronic disease requiring ongoing management or lifelong monitoring, often progressive.
Cost of Treatment (Initial)
High, involving diagnostics, surgery, and initiation of systemic therapy (e.g., tens of thousands of dollars).
Cost of Treatment (Lifetime)
Very high, encompassing long-term systemic therapies, follow-up, and management of recurrence or progression (e.g., hundreds of thousands of dollars).
Mortality Rate
High, as it indicates regional spread of cancer, significantly worsening prognosis compared to localized disease (e.g., 20-50% depending on primary cancer and stage).
Risk of Secondary Damages
High, including lymphedema, pain, nerve damage, and side effects from systemic therapies (e.g., >50%).
Probability of Full Recovery
Low probability of complete recovery without consequences, as regional metastases indicate advanced disease with high recurrence risk (e.g., <30%).
Underlying Disease Risk
100%, as achselmetastasen are always a secondary manifestation of a primary underlying cancer (e.g., breast cancer, melanoma).